NCT Number: NCT00298688
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Research Site, Copenhagen, Denmark
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Provision of written informed consent
- Histologically confirmed, relapsed or refractory SCLCr
- Aged 18 or over and a life expectancy of more than 2 months
Exclusion criteria
- Any evidence of clinically active interstitial lung disease
- Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ.
Treatment and study plan
Primary outcomes
-
To determine the disease control rate in these patients
Secondary outcomes
-
To determine the objective response rate at trail closure in these patients
-
To determine the time to progression-or-death in these patients
-
To determine overall survival in these patients
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
AstraZeneca
Industry
Registry information
Official study title
Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer
Important dates
- Study start
- 2004
- Study completion
- 2007
- First posted
- Mar 3, 2006
- Registry last updated
- Jun 12, 2008
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
NCT04209595
Bronchial Neoplasms, Carcinoma, Bronchogenic
Bethesda, Maryland, United States
View Trial DetailsSmall Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
NCT02046733
Bronchial Neoplasms, Carcinoma, Bronchogenic
Bendigo, Australia
View Trial DetailsEfficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
NCT04924101
Bronchial Neoplasms, Carcinoma, Bronchogenic
Gilbert, Arizona, United States
View Trial DetailsA Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
NCT03782207
Adenocarcinoma, Bronchial Neoplasms
Buenos Aires, Argentina
View Trial Details